ArticleCureus2025
Neutrophil-Lymphocyte Ratio as a Potential Biomarker for Schizophrenia Severity: A Cross-Sectional Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Complete blood count-derived inflammatory markers in schizophrenia: towards an integrated framework.European archives of psychiatry and clinical neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchizophrenia is a chronic psychiatric disorder with a complex etiology, and inflammation has been increasingly implicated in its pathophysiology. The neutrophil-lymphocyte ratio (NLR), a simple hematological marker, may serve as an adjunctive biomarker for disease severity.
objectiveTo evaluate the association between NLR and schizophrenia severity, and to compare inflammatory status between treated and untreated patients.
methodsA hospital-based cross-sectional study was conducted among 100 patients with International Classification of Diseases, Tenth Revision (ICD-10)-diagnosed schizophrenia. Of 143 patients screened, 43 were excluded. Symptom severity was assessed using the Brief Psychiatric Rating Scale (BPRS). Complete blood counts were analyzed to calculate NLR. Statistical analysis included Welch's t-test, chi-square test, and Pearson's correlation (α = 0.05).
resultsThe mean age of participants was 47.9 ± 8.6 years; 73% were male. Fifty-nine patients were treated, and 41 were untreated. Untreated patients had significantly higher NLR values (8.94 ± 5.08 vs. 4.57 ± 1.90; p < 0.001). The mean BPRS score was 61.9 ± 17.3. NLR correlated strongly with BPRS (r = 0.736, p < 0.001).
conclusionElevated NLR is associated with greater schizophrenia severity and higher values in untreated patients. NLR, being inexpensive and widely available, could serve as an adjunctive tool for routine monitoring and personalized management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.